This document provides information on medical nutrition therapy for a patient with end-stage renal disease undergoing hemodialysis. The patient has a GFR of 12 mL/min and receives hemodialysis twice a week. The goals of medical nutrition therapy are to prevent deficiencies, control fluid balance and electrolytes, and prevent complications related to calcium and phosphorus levels. The dietitian provides calculations to determine the patient's energy, protein, fluid and electrolyte needs and prescribes an appropriate diet.
Medical Nutrition Therapy for Cardiovascular Diseases, Krause Book 14th editionBatoul Ghosn
Prepared from the chapter of MNT of CVD from Krause's book 14 the edition 2017 as well as some part from " Modern Nutrition in health and disease" 11th edition.
This presentation deals with the various approaches of medical nutrition therapy in Diabetes, comparison of the ADA, RSSDI and ICMR guidelines. It also talks about the various calorie counting apps as well.
What exactly is a renal diet is asked by many people as they are concerned about possible kidney disease. Discover 4 important tips and recommended foods to strengthen your kidneys and deter kidney disease
Medical Nutrition Therapy for Cardiovascular Diseases, Krause Book 14th editionBatoul Ghosn
Prepared from the chapter of MNT of CVD from Krause's book 14 the edition 2017 as well as some part from " Modern Nutrition in health and disease" 11th edition.
This presentation deals with the various approaches of medical nutrition therapy in Diabetes, comparison of the ADA, RSSDI and ICMR guidelines. It also talks about the various calorie counting apps as well.
What exactly is a renal diet is asked by many people as they are concerned about possible kidney disease. Discover 4 important tips and recommended foods to strengthen your kidneys and deter kidney disease
This presentation is based on JBDS and BSPDE guidelines in adult and Paediatric DKA management. A comparison of adult vs paediatric management is included.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
2. Case 3: ESRD Hemodialysis
• GFR = 12 mL/min
• Kidney not immediately available, hemodialysis was
recommended
• Arteriovenous fistula was created on his left forearm
• BP na d serum potassium level has risen and BUN is 110 mg/dL
• HD is twice a week
• Instructed to continue phosphate binders and calcium
supplements
• Post-dialysis weight gain is 54 kg
3. Pathophysiology
• End Stage Renal Disease can result from a wide variety of
different kidney diseases
– Diabetes Mellitus
– Hypertension
– Glomerulonephritis or Acute Kidney Failure
– Chronic Kidney Failure
• Diagnosis: Stage 5 CKD, BUN 100 mg/dL, Cr 10-12 mg/dL
4. Medical Treatment
• Options include
– Dialysis <3
– Transplantation
– Medical management progressing to death
5. Dialysis
• Px may choose if he/she prefers:
– Outpatient dialysis facility
– Hemodialysis at home
– Peritoneal Dialysis
• Continuous Ambulatory Peritoneal Dialysis (CAPD)
• Continuous Cyclic Peritoneal Dialysis (CCPD)
6. Factors to consider in type of Dialysis Treatment
• Availability of family/friends/caretaker to assist therapy
• Type of water supply ate home
• Previous abdominal surgeries
• Membrane characteristics of Peritoneal Membrane
• Body size, cardiac status, presence of vascular access
• Desire to travel
7. What is Hemodialysis?
• Hemodialysis requires permanent access to blood stream
through a FISTULA
– If the patient’s blood vessels are fragile, a GRAFT is necessary
• Large needles are inserted into the fistula or graft each
dialysis and removed when dialysis is complete
• HD’s fluid is similar to that of a Human’s Plasma
• Waste Products and Electrolytes are removed by diffusion,
ultrafiltration, and osmosis from the dialysate
• Usually 3 to 5 hours ; newer treatments are shorter
8.
9. What is Peritoneal Dialysis
• Uses the body’s PERITONEUM
• Dialysate containing High-dextrose solution is installed in the
peritoneum
– Diffusion ; blood dialysate (wastes)
– Osmosis (water)
• Advantage compared to HD: avoids large fluctuations in blood
chemistry, longer residual renal function and ability of the
patient to live a normal lifestyle
• Complications: Peritonitis, Hypotension and WEIGHT GAIN
• Icodextrin – superior fluid removal without dextrose absorption
10.
11. Evaluation of Dialysis Frequency
• Kinetic Modeling
– Measures the removal of urea from the patient’s blood over a given
period
– Kt/V
• K – Urea Clearance
• t – Length of time of dialysis
• V – Total Body Water Volume
• Urea Reduction Ratio
– Looks ate the reduction of urea after dialysis
13. Medical Nutrition Therapy Goals
• Prevent deficiency and maintain good nutrition status
through adequate protein, energy, vitamin and mineral
intake
• Control edema and electrolyte imbalance by controlling
sodium, potassium and fluid intake
• Prevent or retard development of renal osteodystrophy by
controlling calcium, phosphorus, Vitamin D and PTH
14. Medical Nutrition Therapy Goals
• Enable the patient to eat a palatable, attractive diet that fits
his or her lifestyle as much as possible
• Coordinate with the Healthcare Team
• Provide initial nutrition education, periodic counseling and
long term monitoring of patients
15. PROTEIN NEEDS
• Dialysis drains body protein
• 1.2 g of Pro for patients who receive HD three times a week
• Albumin is a limited factor of protein nutriture, but is
routinely used in evaluating ESRD’s NS
• Patients with Uremia have greater chances of lowered
protein intake
• Patients may tolerate other sources of meats better
• Phosphate restriction may be lifted to allow dairy products
16. Energy
• SHOULD BE ADEQUATE TO SPARE PROTEIN
• 25 kcal – 40 kcal/g of body weight
• Higher needs for patients in PD
17. Fluid and Sodium Balance
• Thirst may indicate excessive sodium intake, increased fluid
gain and resultant hypertension
• Allowed weight gain (fluid gain) for HD patients – 2 to 4
kilograms
• Restriction on fluid: 750 ml + urine output
• Some patients may have salt wasting tendencies which maye
require extra sodium
• Frequent dialyses, daily PD, daily nocturnal dialysis – higher
allowance for sodium and fluid
18. Potassium
• Restriction would be based on the frequency of
Hemodialysis
• Be careful: Low sodium foods contain potassium chloride as
a salt substitute
19. Phosphorus
• As GFR decreases, phosphorus excretion also decreases
• High-protein diet may also be equated to high phosphorus
intake
• Phosphate binders
– May cause GI distress, diarrhea or gas
– Severe constipation intestinal impaction
20. Calcium and Parathyroid Hormone
• ESRD patients Impaired Calcium and PTH balance
• As GFR decreases, serum calcium declines because
– Decreased ability to convert Vit. D
– Increased need due to high phosphorus intake
– Hypertrophy of the Parathyroid gland
• Over secretion of PTH
• Secondary hyperparathyroidism
• Calciphylaxis
– Deposition in wound tissues with resultant vascular calcification,
thrombosis, non-healing wounds and gangrene
21. Lipids
• Risk of atherosclerotic cardiovascular diseases
• Elevated TG without increase in cholesterol
• Low cholesterol levels may lead to mortality of ESRD
22. Iron and EPO
• ESRD inability of the kidney to produce EPO
• EPO – stimulates bone marrow to produce red blood cells
• There is also a destruction of red blood cells
• Lost blood in dialysis
RISK FOR ANEMIA
23. Vitamins
• Water soluble vitamins -> lost during dialysis
• Emphasis on Folate
• Vitamin B12 is protein bound, thus, losses are minimal
• High Phosphorus foods -> High water soluble vitamins
• Niacin -> helpful in lowering phosphate levels in ESRD
patients
24. Case Study: Dietary Computations
• Desirable Body Weight
– (172.27 cm – 100) x .90
– 65 kg
• Dry Body Weight
– NTBW = 54 kg x .50
– =27
– ATBW = (142 mEq/L / 140 mEqL x NTBW)
– =27.38
25. Dietary Computations
• EBW = 27.38 – 27 kg
• EBW = 0.38 L
• Estimated Dry Weight – 53.62 kg
• Estimated BMI = 18.0 (Underweight)
27. Protein Requirement
• = DBW x 1.2 g/KDBW
• = 78 g Pro ῀ 80 g Pro
• NPC = 2250 – (80 g Pro x 4 kcal/g)
• NPC = 1930 kcal
Based on the Diet Manual
28. Non-Protein Calories Distribution
Carbohydrates
• 1930 kcal x .70
• = 1351 kcal / (4 kcal/g)
• = 337.75 g CHO
• = 340 g CHO
Fat
• 1930 kcal x .30
• = 579 kcal / (9 kcal/g)
• = 64.5 g Fat
• = 65 g Fat
29. Phosphorus, Potassium and Sodium Restriction
• Potassium
– DBW X 40 mg/KgIBW
– =2600 mg or 2 g - 3 g Potassium
• Phosphorus
– DBW x < 17 mg / Kg DBW
– = < 1105 mg
• Sodium
– 2 – 3 g
30. Fluid and Restriction
• Fluid
– 750 mL – 1000 ml / Day
• Calcium
– 1000 mg – 1800 mg (supplements as needed)
31. Final Diet Prescription
• 2250 kcal ; 340 g CHO ; 80 g Pro ; 65 g Fat
– 2 – 3 g Potassium
– < 1105 Phosphorus
– 750 mL – 1000 mL Fluid
– 2 – 3 g Sodium
– 1000 mg – 1800 mg Calcium
32. Distribution to Exchanges
Food Group
Ex CHO (g) PRO (g) FAT (g) KCAL Na K Ca P Moisture
Veg A 2 3 1.2 32 4 120 30 30 60
Veg A.1 2 3 1.2 32 4 240 80 30 60
Fruit B (Processed) 3 30 0.6 120 6 180 15 15 126
Sugar A 5 25 100 35 100 75 100 10
Sugar (Free Foods) 10 50 200 0 0 0 0 0
Rice A 8 184 16 800 16 480 120 280 600
Rice B 2 46 8 200 460 120 40 70 20
Meat (Lean) A 6 48 6 246 180 1200 90 420 186
Fat A 2 10 90 80 4 2 2 2
Fat (Free Foods) 9 45 405 0 0 0 0 0
TOTAL 341 75 61 2225 785 2444 452 947 1064
DM – Advanced glycosylation end products
AKR – Pre-renal, intrerenal
400-800 CALORIES ABSORBED
Kapag underweight okay lang pero account for the calories absorbed
Kapag DM or Overweight, pwede gumamit ng Icodextrin – removes fluid without excess absorption
Idea
Relevance: Px with low albumin levels – GREATER MORTALITY